
Helus Pharma reported positive topline results from a Phase III trial of HLP003 as an add-on treatment for major depressive disorder, saying the study met its primary and key secondary endpoints at six and 12 weeks.
Patients receiving HLP003 had a 7.6-point greater reduction in depressive symptoms than those receiving placebo at week six, as measured by the Montgomery-Åsberg Depression Rating Scale, or MADRS. The difference was seven points at week 12, the company said.
Chief Executive Officer Michael Halstead said the results showed a rapid and durable treatment effect in patients who had not responded adequately to their existing antidepressants. HLP003 remains investigational, and a second Phase III efficacy study is ongoing.
Trial Results
The randomized, double-blind APPROACH study enrolled adults with moderate to severe depression who remained symptomatic despite taking an adequately dosed antidepressant. Participants continued their existing medication and received two administrations of either 16 milligrams of HLP003 or placebo, three weeks apart.
Chief Medical Officer Amir Inamdar said the average participant was about 45 years old and most were women. The trial excluded patients with treatment-resistant depression, bipolar disorder, psychotic disorders, clinically significant suicidality, substance use disorder or recent psychedelic exposure.
At week six, the adjusted mean reduction in MADRS score was 19.5 points for HLP003 and 11.9 points for placebo. The difference was statistically significant, as was the seven-point difference at week 12, Inamdar said. He added that the treatment effect emerged by day two and remained statistically significant at subsequent assessments through week 12.
Helus said 56% of patients receiving HLP003 met the trial’s definition of response at week six, meaning their MADRS score had fallen by at least half. At that point, 51% were in remission, defined as a score of 10 or less. At week 12, the respective figures were 45% and 40%.
Inamdar said 39% of patients receiving HLP003 were in remission on day two, following the first dose. Asked whether the same patients remained in remission through week 12, he said the company had not formally analyzed sustained remission and would disclose that analysis with a fuller dataset.
Safety and Next Steps
Inamdar said most adverse events were mild to moderate and occurred and resolved on the day of dosing. There were three treatment-related serious adverse events in the HLP003 group and none in the placebo group, he said. Two participants discontinued because of adverse events.
One serious event was a suicide attempt by a participant who had not responded to treatment. Inamdar said the attempt occurred 55 days after the second dose and involved an overdose of the participant’s background antidepressant. The participant was hospitalized and subsequently discharged.
Inamdar said the participant had a prior history of a suicide attempt and that Helus had not observed a suicidality signal in its assessment of the study. Halstead said he did not expect the safety findings to negatively affect discussions with the Food and Drug Administration.
Helus expects results from its second Phase III efficacy study, EMBRACE, in the fourth quarter of 2027. A long-term extension study, EXTEND, is also underway to assess durability and retreatment. Halstead said the company remains prepared for a potential new drug application filing in 2028.
About Cybin (NASDAQ:HELP)
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
